Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH3809 in Advanced Solid Tumors
NCT04843033Phase 1Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SH3809 in solid tumor (advanced stage), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
SH3809
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04843033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843033.